VRE Infections: When Are Linezolid and Daptomycin Used?

Why do VRE infections matter after the COVID-19 pandemic?

The CDC's COVID-19 and antimicrobial resistance overview, updated February 5, 2025, describes setbacks during earlier pandemic years. Across seven resistant pathogens, hospital-onset infections and deaths each increased by at least 15% from 2019 to 2020. Hospitals faced staffing shortages, longer admissions and greater use of invasive devices. These historical findings provide the context for treatment challenges; they are not estimates of infection rates in October 2026. [CDC pandemic overview](https://www.cdc.gov/antimicrobial-resistance/data-research/threats/covid-19.html).

Enterococci normally live in the intestines, but they can cause infections in vulnerable patients. Vancomycin-resistant enterococci, or VRE, withstand an antibiotic often used against these bacteria. CDC identifies prolonged antibiotic exposure, surgery, medical devices and weakened immunity as risk factors. Most VRE infections occur in hospitals. Laboratory testing helps clinicians identify which alternative antibiotics may work, while distinguishing infection from symptom-free carriage prevents unnecessary treatment. [CDC VRE guidance](https://www.cdc.gov/vre/about/index.html).

How do linezolid and daptomycin fit into VRE treatment?

Linezolid blocks bacterial protein production. Its U.S. prescribing information includes vancomycin-resistant Enterococcus faecium infections, including cases with accompanying bloodstream infection. Approximately 100% oral bioavailability means an oral dose can provide systemic exposure comparable to intravenous administration, supporting a clinician-directed switch when appropriate. [Linezolid prescribing information](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=374af2a7-d994-40bd-a86a-cd9038d0b72c).

Daptomycin disrupts bacterial cell membranes and is administered intravenously. Its labeled indications do not include VRE bloodstream infection, so this use is off-label. That distinction matters: evidence from clinical practice must be interpreted separately from the trials supporting its approved indications. [Daptomycin prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e1f739a-eb81-43d8-9a14-89f32b7e1ba1).

A retrospective study published in Clinical Infectious Diseases in 2017 examined 911 patients treated with daptomycin for VRE bloodstream infections. Higher-dose treatment was associated with better survival and faster clearance of bacteria than standard-dose treatment. However, only 60 patients received the highest-dose strategy, and treatment was not randomly assigned. Differences between patients could influence the results despite statistical adjustment. The study supports further investigation of dose optimization; it does not establish that daptomycin is superior to linezolid, which was not the comparator. [Britt and colleagues' cohort study](https://pubmed.ncbi.nlm.nih.gov/28011602/).

What monitoring is needed during VRE antibiotic treatment?

Linezolid can suppress blood-cell production, and its label recommends weekly complete blood counts. Clinicians also review serotonergic medicines, including certain antidepressants and opioids, because combinations can cause serotonin syndrome. Nerve and visual complications are additional concerns, particularly during prolonged courses. Patients should report new visual symptoms promptly. [Linezolid safety information](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=374af2a7-d994-40bd-a86a-cd9038d0b72c).

Daptomycin can cause muscle injury. Its label recommends weekly creatine phosphokinase testing, with closer monitoring in specified circumstances, including kidney impairment or concurrent statin treatment. Kidney function also affects dosing decisions. New muscle pain or weakness warrants prompt clinical review. These differences make safety monitoring part of antibiotic selection, alongside the organism's susceptibility and the patient's condition. [Daptomycin safety information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e1f739a-eb81-43d8-9a14-89f32b7e1ba1).